Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Combination Immunotherapy with NY-ESO-1-Specific CAR + T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect

Krina Patel, MD, Simon Olivares, BS, Harjeet Singh, PhD, Lenka V. Hurton, PhD, Mary Helen Huls, BS, Muzaffar H. Qazilbash, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Laurence J.N. Cooper, MD PhD

Blood (2016) 128 (22): 3366.

https://doi.org/10.1182/blood.V128.22.3366.3366

Published: 2016

Journal Articles

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies

Blood (2015) 126 (23): 862.

https://doi.org/10.1182/blood.V126.23.862.862

Published: 2015

Journal Articles

Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor

Blood (2014) 124 (21): 311.

https://doi.org/10.1182/blood.V124.21.311.311

Published: 2014

Journal Articles

Targeting An Ancient Retrovirus In Tumor Using Engineered T Cells

Janani Krishnamurthy, Brian Rabinovich, Simon Olivares, BS, Mi Teijuan, Kirsten Switzer, Joshua Plummer, Sourindra Maiti, PHD, Harjeet Singh, PhD, Helen Huls, BS, Feng-wang Johanning, Laurence J N Cooper, MD, PhD

Blood (2013) 122 (21): 4206.

https://doi.org/10.1182/blood.V122.21.4206.4206

Published: 2013

Journal Articles

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor

Partow Kebriaei, MD, Helen Huls, BS, Harjeet Singh, PhD, Simon Olivares, BS, Matthew Figliola, BS, Pappanaicken R Kumar, BS, Bipulendu Jena, PhD, Rineka N Jackson, BBA, Tingting Liu, BS, Ian K. McNiece, PhD, Gabriela Rondon, MD, Perry Hackett, PhD, Richard E Champlin, MD, Elizabeth J Shpall, MD, Laurence J N Cooper, MD, PhD

Blood (2013) 122 (21): 4208.

https://doi.org/10.1182/blood.V122.21.4208.4208

Published: 2013

Journal Articles

First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor

Partow Kebriaei, MD, Helen Huls, BS, Harjeet Singh, PhD, Simon Olivares, BS, Matthew Figliola, BS, Pappanaicken R. Kumar, BS, Bipulendu Jena, PhD, Marie Andree Forget, Sonny Ang, PhD, Rineka N. Jackson, BBA, Tingting Liu, BS, Doyle Bosque, ADN, Ian K. McNiece, PhD, Gabriela Rondon, MD, Perry Hackett, PhD, Chitra M. Hosing, MD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Laurence J N. Cooper, MD, PhD

Blood (2013) 122 (21): 166.

https://doi.org/10.1182/blood.V122.21.166.166

Published: 2013

Journal Articles

Targeting Leukemias by CD123 Specific Chimeric Antigen Receptor

Radhika Thokala, MS, Harjeet Singh, PhD, Simon Olivares, BS, Richard Champlin, MD, Laurence J N Cooper, MD, PhD

Blood (2011) 118 (21): 1908.

https://doi.org/10.1182/blood.V118.21.1908.1908

Published: 2011

Journal Articles

The Contribution of Signaling Endodomains to CD33-Mediated Killing of Acute Myeloid Leukemia by Natural Killer Cells Transiently Modified with Chimeric Antigen Receptor.

Jeffrey Friesen, Vladimir Senyukov, PhD, Cecele J Denman, Srinivas S. Somanchi, PhD, Simon Olivares, BS, Laurence J.N. Cooper, MD PhD, Dean A. Lee, MD, PhD

Blood (2009) 114 (22): 2463.

https://doi.org/10.1182/blood.V114.22.2463.2463

Published: 2009

Journal Articles

Gene Modification of Human Primary Natural Killer Cells by Electroporation with mRNA or DNA Coding for An Anti-GD2 Chimeric Antigen Receptor.

Srinivas S. Somanchi, Ph.D, Cecele J Denman, MS, Atharva Amritkar, Vladimir Senyukov, Ph.D, Simon Olivares, BS, Laurence J.N Cooper, MD, Ph.D, Dean A. Lee, MD, Ph.D

Blood (2009) 114 (22): 2467.

https://doi.org/10.1182/blood.V114.22.2467.2467

Published: 2009

Journal Articles

IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.

Lenka V. Hurton, MS, Harjeet Singh, PhD, Simon Olivares, BS, Sonny O. Ang, PhD, Susan Staba Kelly, MD, Partow Kebriaei, MD, Dean A. Lee, MD, PhD, Richard E. Champlin, MD, Laurence J.N. Cooper, MD

Blood (2009) 114 (22): 3035.

https://doi.org/10.1182/blood.V114.22.3035.3035

Published: 2009

Journal Articles

Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21.

Cecele J Denman, MS, Lisa M. Kopp, DO, Vladimir Senyukov, PhD, Sarah Hagemeister, Jennifer Johnson, Maria A Lima Da Silva, Harjeet Singh, PhD, Lenka Hurton, Simon Olivares, BS, Mary Helen Huls, BS, Richard E Champlin, MD, Laurence J.N. Cooper, MD, PhD, Dean A. Lee, MD, PhD

Blood (2009) 114 (22): 3030.

https://doi.org/10.1182/blood.V114.22.3030.3030

Published: 2009

Journal Articles

Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.

Harjeet Singh, PhD, Hillary N Gibbons, BS, Simon Olivares, BS, Matthew J. Figliola, BS, Margaret J. Dawson, BS, Mary Helen Huls, BS, Dean A Lee, MD, Ph.D, Partow Kebriaei, MD, Richard E Champlin, MD, Laurence J.N. Cooper, MD, PhD

Blood (2009) 114 (22): 4097.

https://doi.org/10.1182/blood.V114.22.4097.4097

Published: 2009

Journal Articles

Conditional T-Cell Activation for Tumor Under Hypoxia

Sonny O Ang, PhD, Simon Olivares, BS, Elizabeth J. Shpall, MD, Dean A. Lee, MD, PhD, Richard Champlin, Patricia Yotnda, PhD, Stephen Gottschalk, MD, Laurence Cooper, MD, PhD

Blood (2008) 112 (11): 3906.

https://doi.org/10.1182/blood.V112.11.3906.3906

Published: 2008

Journal Articles

Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas.

Harjeet Singh, PhD, Lisa Marie A. Serrano, BS, Simon Olivares, BS, Michael Jensen, MD, George McNamara, PhD, David Colcher, MD, Andrew Raubitschek, MD, Laurence J.N. Cooper, MD, PhD

Blood (2005) 106 (11): 343.

https://doi.org/10.1182/blood.V106.11.343.343

Published: 2005

Journal Articles

CD28-Costimulation Provided through a CD19-Specific Chimeric Immunoreceptor Enhances In Vivo Persistence and Anti-Tumor Efficacy of Adoptively Transferred T Cells.

Claudia M. Kowolik, PhD, Sergio Gonzalez, BS, Simon Olivares, BS, Michael Jensen, MD, Laurence J.N. Cooper, MD, PhD

Blood (2005) 106 (11): 1278.

https://doi.org/10.1182/blood.V106.11.1278.1278

Published: 2005

Journal Articles

Artificial Antigen Presenting Cell Can Be Used To Propagate Genetically Modified CD19-Specific T Cells through Chimeric Antigen Receptor.

Tontanai Numbenjapon, MD, Lisa Marie A. Serrano, BS, Simon Olivares, BS, Wen-Chung Chang, BS, Harjeet Singh, PhD, Claudia M. Kowolik, PhD, Sergio Gonzalez, BS, Nancy Gonzalez, BS, Laurence J.N. Cooper, MD/PhD

Blood (2005) 106 (11): 1295.

https://doi.org/10.1182/blood.V106.11.1295.1295

Published: 2005

Journal Articles

Cord Blood-Derived T Cells Can Be Genetically Engineered to Be B-Lineage All-Specific: Towards Adoptive Immunotherapy after Umbilical Cord Blood Transplantation.

Laurence J.N. Cooper, MD, PhD, Lisa Marie Serrano, BA, Zaid Al-Kadhimi, MD, Simon Olivares, BS, Sergio Gonzalez, BA, Timothy Pfeiffer, BS, Joseph Rosenthal, MD, Steven J. Forman, MD, Michael C. Jensen, MD

Blood (2004) 104 (11): 48.

https://doi.org/10.1182/blood.V104.11.48.48

Published: 2004

Journal Articles

T Cells Genetically Modified to Be CD19-Specific with Improved Potential for Trafficking and Activation.

Zaid Al-Kadhimi, MD, Lisa Marie Serrano, BA, Simon Olivares, BS, Sergio Gonzalez, BA, Timothy Pfeiffer, BS, Reena Vishwanath, BA, Michael C. Jensen, MD, Steven J. Forman, MD, Laurence J.N. Cooper, MD, PhD

Blood (2004) 104 (11): 1748.

https://doi.org/10.1182/blood.V104.11.1748.1748

Published: 2004

NARROW

Combination Immunotherapy with NY-ESO-1-Specific CAR + T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies

Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor

Targeting An Ancient Retrovirus In Tumor Using Engineered T Cells

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor

First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor

Targeting Leukemias by CD123 Specific Chimeric Antigen Receptor

The Contribution of Signaling Endodomains to CD33-Mediated Killing of Acute Myeloid Leukemia by Natural Killer Cells Transiently Modified with Chimeric Antigen Receptor.

Gene Modification of Human Primary Natural Killer Cells by Electroporation with mRNA or DNA Coding for An Anti-GD2 Chimeric Antigen Receptor.

IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.

Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21.

Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.

Conditional T-Cell Activation for Tumor Under Hypoxia

Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas.

CD28-Costimulation Provided through a CD19-Specific Chimeric Immunoreceptor Enhances In Vivo Persistence and Anti-Tumor Efficacy of Adoptively Transferred T Cells.

Artificial Antigen Presenting Cell Can Be Used To Propagate Genetically Modified CD19-Specific T Cells through Chimeric Antigen Receptor.

Cord Blood-Derived T Cells Can Be Genetically Engineered to Be B-Lineage All-Specific: Towards Adoptive Immunotherapy after Umbilical Cord Blood Transplantation.

T Cells Genetically Modified to Be CD19-Specific with Improved Potential for Trafficking and Activation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only